Beta Cell Glucose Sensitivity May Predict Response to New-Onset Type 1 Diabetes Therapies

Study Title and Why It Matters

Beta cell glucose sensitivity may help predict which people newly diagnosed with type 1 diabetes are more likely to benefit from disease-modifying therapy started at stage 3, the point at which the disease becomes clinically apparent and insulin treatment is required. This is an important question because, despite many clinical trials over several decades, there are still no widely approved disease-modifying therapies for people at new-onset type 1 diabetes. Most treatments are still focused on insulin replacement rather than preserving the body’s own insulin-producing capacity.

The study examined whether a model-based measure called beta cell glucose sensitivity, or βGS, could do a better job than traditional markers at identifying treatment response. In simple terms, βGS reflects how strongly surviving beta cells respond to rising blood glucose. If beta cells remain more “glucose-sensitive,” they are likely still functioning better and may be more amenable to preservation by therapy.